Status:
COMPLETED
Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular h...
Eligibility Criteria
Inclusion
- Glaucoma and/or ocular hypertension in both eyes
- Requires IOP-lowering treatment in both eyes
Exclusion
- Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
- Current or anticipated use of ocular medications other than study medications, except for intermittent use of artificial tears
- Use of oral, injectable or topical corticosteroids within 21 days
- Iridectomy or laser peripheral iridotomy in the study eye within 3 months
- Uncomplicated cataract surgery in the study eye within 6 months
- Incisional glaucoma surgery in the study eye within 12 months
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT01216943
Start Date
November 1 2010
End Date
August 1 2012
Last Update
September 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Coimbatore, Tamil Nadu, India